                         SEQUENCE LISTING

<110>  ProQR Therapeutics II B.V.
 
<120>  RNA EDITING INHIBITORS AND METHODS OF USE

<130>  P3675GB00-GJ2NE

<160>  29    

<170>  PatentIn version 3.5

<210>  1
<211>  328
<212>  RNA
<213>  Mus musculus

<400>  1
ccuuccugag cuaccacccg uacccuuucu cccagcgcac acuuacugcu cgauuccagg       60

ucaacaauac ucacccaccc cacgugcagu ugcugcgaaa gccaguacuc acagucaugg      120

ggcucauggc ccuguuggau ggagaacaac ucuaggcaga ggucucaaag gcuggggcug      180

uguuggacag caaucauaca gugggugucc uggccagcac ccaucacccu gaaggcuccg      240

cagcggccug gaguaccaca guccucaucu acacuaguga ugacacccac gcacacccca      300

accuacguuu ccagucgguc cacguuug                                         328


<210>  2
<211>  40
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  antisense oligonucleotide

<400>  2
cacagcccca gccuuugaga ccucugccca gaguuguucu                             40


<210>  3
<211>  57
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  antisense oligonucleotide

<400>  3
gmcmcmcmcm amgmcmcmum umumgmamgm amcmcmumcu gcccagaguu guucucc          57


<210>  4
<211>  61
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  antisense oligonucleotide

<400>  4
gmcmcmcmcm amgmcmcmum umumgmamgm amcmcmumcm umgmcmccag aguuguucuc       60

c                                                                       61


<210>  5
<211>  78
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  antisense oligonucleotide

<400>  5
cmamcmamgm cmcmcmcmam gmcmcmumum umgmamgmam cmcmumcmum gmumcmcmam       60

gmamgmumum gmumumcm                                                     78


<210>  6
<211>  39
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  antisense oligonucleotide

<400>  6
cacagcccca gccuuugaga ccucugucca gaguuguuc                              39


<210>  7
<211>  71
<212>  DNA
<213>  Mus musculus

<400>  7
ggggctcatg gccctgttgg atggagaaca actctaggca gaggtctcaa aggctggggc       60

tgtgttggac a                                                            71


<210>  8
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer

<400>  8
agtactcaca gtcatggggc tca                                               23


<210>  9
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer

<400>  9
gccaggacac ccactgtatg at                                                22


<210>  10
<211>  16
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Primer

<400>  10
tggggctcat ggccct                                                       16


<210>  11
<211>  61
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  A or G Construct

<400>  11
gttggatgga gaacaactct argggcagag gtctcaarga ggctggggct gtgttggaca       60

g                                                                       61


<210>  12
<211>  56
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Dispensation order

<400>  12
agctgactgg agagcgagct catagtcaga gtctgcgaga gctggctgtg ctgaca           56


<210>  13
<211>  38
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  dispensation order

<400>  13
cgtgatgaga cactcgtagc agagtctgca gagctgca                               38


<210>  14
<211>  71
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  A or G construct

<400>  14
gttggargtg garggaacaa rgctctargg gcarggaggt ctcaaarggg ctggggctgt       60

gttggargca g                                                            71


<210>  15
<211>  64
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ESS of XIAP

<400>  15
gttgcccagg atggagtgca atggcacaat cttggctcat ggcaaactct gcctcgcaag       60

cgga                                                                    64


<210>  16
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  ESS of 5-HT2RC

<400>  16
tatcgctgga tcggtatgta gcaatacgta atcctattga gcatagccgt t                51


<210>  17
<211>  24
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  24-mer AON targeting XIAP

<400>  17
gagccaagau ugugccauug cacu                                              24


<210>  18
<211>  19
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  19-mer AON targeting XIAP

<400>  18
ccaagauugu gccauugca                                                    19


<210>  19
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  24-mer AON targeting 5-HT2RC

<400>  19
aggauuacgu auugcuacat accg                                              24


<210>  20
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  19-mer AON targeting 5-HT2RC

<400>  20
uacguauugc uacataccg                                                    19


<210>  21
<211>  11
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fig 7A

<400>  21
arttgcacar t                                                            11


<210>  22
<211>  11
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Figure 7B

<400>  22
aattgcacaa t                                                            11


<210>  23
<211>  10
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fig 8A and B

<400>  23
gcartacgta                                                              10


<210>  24
<211>  19
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  XIAP forward PCR primer

<400>  24
ctactccgga gcctgaggt                                                    19


<210>  25
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  XIAP reverse PCR primer

<400>  25
tgggagatga atcacttgag gt                                                22


<210>  26
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  XIAP sequencing primer

<400>  26
cagaaattca agactagcct ggc                                               23


<210>  27
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  5-HT2RC forward PCR primer

<400>  27
ggcaatcctt tatgattatg tctgg                                             25


<210>  28
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  5-HT2RC reverse PCR primer

<400>  28
tgcccaaaca atagcaatct tca                                               23


<210>  29
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  5-HT2RC sequencing primer

<400>  29
tcatgatggc cttagtccgc                                                   20


